BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23743818)

  • 1. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.
    Cappellano AM; Senerchia AA; Adolfo F; Paiva PM; Pinho R; Covic A; Cavalheiro S; Saba N
    Childs Nerv Syst; 2013 Dec; 29(12):2301-5. PubMed ID: 23743818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
    Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
    N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
    Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D; Franz DN
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.
    Yalon M; Ben-Sira L; Constantini S; Toren A
    Childs Nerv Syst; 2011 Jan; 27(1):179-81. PubMed ID: 20703486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus.
    Aguilera D; Flamini R; Mazewski C; Schniederjan M; Hayes L; Boydston W; Castellino RC; MacDonald TJ
    J Pediatr Hematol Oncol; 2014 Oct; 36(7):e448-51. PubMed ID: 24276039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
    Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
    BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
    Franz DN; Agricola K; Mays M; Tudor C; Care MM; Holland-Bouley K; Berkowitz N; Miao S; Peyrard S; Krueger DA
    Ann Neurol; 2015 Dec; 78(6):929-38. PubMed ID: 26381530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus.
    Arroyo MS; Krueger DA; Broomall E; Stevenson CB; Franz DN
    Pediatr Neurol; 2017 Jul; 72():81-85. PubMed ID: 28511812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P
    Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
    Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Curran MP
    Paediatr Drugs; 2012 Feb; 14(1):51-60. PubMed ID: 22136276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.
    Fukumura S; Watanabe T; Takayama R; Minagawa K; Tsutsumi H
    J Child Neurol; 2015 Aug; 30(9):1192-5. PubMed ID: 25143481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.